Migraine drug NURTEC under Real-World safety watch in korea
NCT ID NCT07497854
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will monitor the safety and effectiveness of NURTEC ODT 75 mg (rimegepant) in 3000 Korean adults with migraine. Participants will take the drug as prescribed for acute attacks or prevention. Researchers will track side effects and how well the drug works, including pain relief within 2 hours and changes in monthly migraine days.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Rimegepant sulfate (NURTEC ODT 75 mg)
- What this could lead to
- If successful, this study could confirm that NURTEC is a safe and effective option for both stopping migraine attacks and preventing them in Korean patients.
- What could go wrong
- This is a post-marketing surveillance study, not a new treatment discovery. It primarily monitors safety in a real-world setting, so no breakthrough is expected. Results may not apply outside Korea.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 3,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2030
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
At least 3000 subjects who are eligible for NURTEC® accoding to its product label will be enrolled by continuous registration method and will be researched under routine clinical setting of Korea.
- Ages
-
19 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. Subjects aged 19 years or older 2. Subjects who administered NURTEC® ODT 75 mg (Rimegepant sulfate) according to the approved label 3. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Migraine, with or without aura are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.